Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine vs placebo in pediatric and adolescent major depressive disorder
2015-002181-23Phase 3Completed
- Sponsor
- Servier
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of agomelatine in major depressive disorder (MDD) (4 arms), sponsored by Servier. Primary endpoint: Children Depression Rating Scale – Revised (CDRS-R) raw score. Started Nov 2015; status: completed.
02
Drugs
agomelatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2015-002181-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002181-23.